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Abstract (196) 124 
U-BIOPRED is an EU consortium of 20 academic institutions, 11 pharmaceutical companies and 6 125 
patient organisations with the objective of improving the understanding of asthma disease 126 
mechanisms using a systems biology approach.  127 
 128 
This cross-sectional assessment of adults with severe asthma, mild/moderate asthma and healthy 129 
controls from 11 European countries consisted of analyses of patient-reported outcomes, lung 130 
function, blood and airway inflammatory measurements.  131 
 132 
Patients with severe asthma (non-smokers n=311 and smokers/ex-smokers n=110) had more 133 
symptoms and exacerbations compared to patients with mild-moderate disease (n=88) (2.5 134 
exacerbations versus 0.4 in the preceding 12 months, p<0.001), with worse quality of life, and higher 135 
levels of anxiety and depression. They also had a higher incidence of nasal polyps and gastro-136 
oesophageal reflux with lower lung function.  Sputum eosinophil count was higher in severe asthma 137 
compared to mild-moderate asthma (median count 2.99% versus 1.05%, p=0.004) despite treatment 138 
with higher doses of inhaled and/or oral corticosteroids. 139 
 140 
Consistent with other severe asthma cohorts, U-BIOPPRED is characterised by poor symptom 141 
control, increased co-morbidity and airway inflammation, despite high levels of treatment. It is well 142 
suited to identify asthma phenotypes using the array of ‘omic’ datasets that are at the core of this 143 
systems medicine approach. 144 
 145 
  146 
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Introduction 147 
A substantial number of patients with asthma require systemic corticosteroids to control symptoms 148 
and/or suffer from poor control and frequent severe exacerbations despite currently available 149 
treatment (1, 2). Although recently-developed biologic compounds targeting cytokines of the Type 2  150 
pathways show promise (3, 4), identification of new treatment targets and the selection of patients 151 
best suited to respond to individual biologics is still hampered by a poor understanding of the 152 
physiological, pathological, and molecular heterogeneity of severe asthma (5, 6).  153 
 154 
Severe asthma is a collection of disease entities with varying pathophysiological characteristics (7) 155 
that result in symptoms of cough, wheeze and breathlessness, with frequent exacerbations. To 156 
address the problem of phenotypic difference and heterogeneity, the Unbiased Biomarkers for the 157 
Prediction of Respiratory Disease Outcomes (U-BIOPRED) project was set up in 2009 as a public-158 
private partnership within the framework of the Innovative Medicines Initiative (IMI), engaging 159 
academia, the pharmaceutical industry and patient groups. The aim of U-BIOPRED is to identify 160 
multi-dimensional phenotypes of severe asthma and new treatment targets using a combination of 161 
state of the art ‘omics’ (transcriptomic, proteomic, lipidomic and metabolomic) technologies 162 
applying a systems biology approach (8) thereby driving unbiased discovery in both adult and 163 
paediatric severe asthma (9). This novel approach is designed to make drug development more 164 
effective and efficient.   165 
 166 
We present the baseline characteristics of the adult participants with severe asthma who form the 167 
majority of the U-BIOPRED cohort and compare these participants with those suffering from with 168 
mild-to-moderate disease, in terms of their clinical, symptomatic, functional and biomarker features. 169 
In a parallel paper the characteristics of the paediatric cohort are reported. These first publications 170 
of U-BIOPRED will serve as the reference documents for all subsequent publications using the ‘omics 171 
technologies which are at the core of this programme. 172 
 173 
Methods 174 
Participants 175 
This was a multi-centre prospective cohort study recruiting from 16 clinical centres in 11 European 176 
countries. Details of the participating centres, assessments, and standard operating procedures are 177 
available in the online supplement. Prior to enrolment, participants with severe asthma were 178 
required to have been under follow-up by a respiratory physician for at least six months during 179 
which time assessments had been undertaken to optimise asthma control and assess medication 180 
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adherence (2). The study was approved by the ethics committee for each participating clinical 181 
institution, and adhered to the standards set by International Conference on Harmonisation and 182 
Good Clinical Practice. It is registered on ClinicalTrials.gov, (Identifier: NCT01982162). All participants 183 
gave written and signed informed consent.  184 
 185 
Adult Groups 186 
The definition of severe asthma used in this study was agreed at a U-BIOPRED consensus meeting 187 
(2). Participants with asthma had either airflow reversibility (increase in FEV1 >12% predicted or 188 
200ml following inhalation of 400µg salbutamol), airway hyper-responsiveness (methacholine PC20 < 189 
8mg/ml, or diurnal PEF amplitude % mean >8%), or a decrease in FEV1 of 12% predicted or 200ml 190 
within 4 weeks after tapering maintenance treatment. Four groups were recruited: 191 
 192 
A) Severe non-smoking asthma (SAn): 193 
Participants in this group were non-smokers for at least the past 12 months, with a less than five 194 
pack-year smoking history, with asthma and uncontrolled symptoms defined according to GINA 195 
guidelines (10) and/or frequent exacerbations (more than two per year) despite high-dose inhaled 196 
corticosteroids (ICS) (ICS ≥ 1000µg fluticasone propionate/day or equivalent dose). 197 
 198 
 B) Smokers and ex-smokers with severe asthma (SAs/ex): 199 
This group was defined as for the SAn group except that they were either current smokers or ex-200 
smokers with a smoking history of at least 5 pack years. 201 
 202 
C) Mild/Moderate non-smoking asthmatics (MMA): 203 
Participants in this group were non-smokers for at least the past 12 months, with a less than five 204 
pack-year smoking history and had controlled or partially controlled asthma symptoms, as defined 205 
by the Global Initiative for Asthma (GINA), whilst receiving a dose of less than 500µg fluticasone 206 
propionate/day or equivalent. 207 
 208 
D) Healthy non-smoking controls (HC): 209 
These participants had no history of asthma or wheeze, had no other chronic respiratory disease, 210 
were non-smokers for at least the past 12 months with a smoking history of ≤ 5 pack years and their 211 
pre-bronchodilator FEV1 was ≥ 80% predicted.  212 
 213 
Protocol and assessments 214 
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Participants attended a screening visit to assess eligibility for the study (Fig 1).  They underwent a 215 
baseline visit (up to 28 days later) and were invited to attend for an optional bronchoscopy, high 216 
resolution lung computed tomography and telemonitoring sessions. Spirometry, haematological 217 
profiles, and fraction of exhaled nitric oxide level (FeNO) at 50ml/sec were performed. Induced 218 
sputum was obtained (11) and differential sputum eosinophil and neutrophil counts measured 219 
following a standardised operating procedure. Sputum supernatants and cell pellets were collected. 220 
Allergic status was obtained by either skin prick testing or measurement of specific IgE to six 221 
common aeroallergens. Blood and urine samples were taken for lipidomic, proteomic and 222 
transcriptomic analyses for later assessment. An optional sample was taken for genetic analysis. 223 
Subsets of participants underwent plethysmographic measurements, high-resolution computed 224 
tomography (HRCT) and collection of exhaled breath for measurement of metabolites including 225 
volatile organic compounds, all for future analyses. All investigations were performed according to 226 
standardised operating procedures (online supplement). 227 
 228 
Participants with severe asthma were reviewed at 12-18 months after enrolment and were also 229 
invited to attend if they experienced an exacerbation. At 12-24 months, they were contacted by 230 
phone or by post to obtain information on asthma control.  231 
 232 
Data were entered on an electronic case report form. The study was run and monitored by 233 
Cromsource (www.cromsource.com). Samples were sent to the Centre for Integrated Genomic 234 
Medical Research Biobank in Manchester, UK. Datasets were uploaded on to the tranSMART system, 235 
an open-source knowledge management platform for sharing research data (12) supported by the 236 
European Translational Information and Knowledge Management Services (eTRIKS) project.  237 
 238 
The study aims are published on the U-BIOPRED home page (www.europeanlung.org/en/projects-239 
and-research/projects/u-biopred/home). 240 
 241 
Questionnaires 242 
The following were administered at baseline: 243 
1.  The Asthma Control Questionnaire (ACQ5) (13) to assess current asthma control. 244 
2.  The Asthma Quality of Life Questionnaire (AQLQ) (14) to assess quality of life and 245 
psychological morbidity. 246 
3.  The Hospital Anxiety and Depression Scale (HADS) (15). 247 
4.  Sino-Nasal Outcomes Test (SNOT20) (16) to measure upper airway symptoms. 248 
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5.  The Epworth Sleepiness Scale (ESS) (17) to measure sleep and daytime drowsiness. 249 
6.  The Medicines Adherence Response Scale (MARS) (18) to measure adherence. 250 
 251 
Statistical Analysis 252 
Continuously distributed data were either summarised using mean (standard error; SE) if 253 
symmetrical, or median (inter-quartile range; IQR) values. Non-symmetrical variables all exhibited 254 
positive skew and were log-transformed prior to association testing. Missing data were not imputed. 255 
P-values were calculated using a general linear model for continuous variables or a general logistic 256 
model for categorical variables. No adjustment for multiple testing was applied as the analyses were 257 
considered exploratory. Analyses were performed using R version 2.15.2 (R Core Team, 2012). 258 
 259 
Results 260 
A total of 610 adults were recruited over an 18-month period: 311, 110, 88 and 101 into the SAn, 261 
SAs/ex, MMA, HC groups respectively (Table i). 262 
  263 
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 N severe 
non-
smoking 
asthma  
 
 
n=311 
smokers 
and ex-
smokers 
with 
severe 
asthma 
n=110* 
mild/moderate 
non-smoking 
asthma 
 
 
 
n=88 
healthy 
non-
smoking 
controls  
 
 
n=101 
P-value 
Age (yr) Mean 
(SE)  
[N] 
51.01 
(0.8)  
[311] 
54.51 
(1.08)  
[110] 
41.66  
(1.65)  
[88] 
38.85 
(1.34) 
[101] 
p<0.001 
Age at 
Diagnosis(yr) 
Median 
(IQR)  
[N] 
20  
(7_38) 
[302] 
38  
(20_48) 
[109] 
14  
(6_32)  
[83] 
NA p<0.001 
Female n/N  
(%) 
205/311 
(66) 
56/110 
(51) 
44/88 
(50) 
39/101 
(39) 
p<0.001 
BMI (kg/m2) Mean 
(SE)  
[N] 
29.11 
(0.36) 
[311] 
29.59  
(0.6)  
[110] 
25.73 
(0.47)  
[88] 
25.31 
(0.36) 
[101] 
p<0.001 
BMI>30 
(kg/m2) 
n/N 
% 
120/311 
(38.6) 
44/110 
(40) 
16/88  
(18.18) 
12/101 
(11.88) 
<0.001 
Serum IgE 
(IU/ml) 
Median 
(IQR) 
[N] 
119.5 
(45_342) 
[302] 
126 
(63_328) 
[104] 
89.4  
(49_244)  
[85] 
23.45 
(9_65) 
[98] 
p<0.001 
FEV1 (%) Mean 
(SE) 
[N] 
67.5 
(1.26) 
[308] 
67.2 
(1.84)  
[110] 
89.5 
(1.86) 
[87] 
101.76 
(1.29) 
[101] 
p<0.001 
FVC (%) Mean 
(SE) 
[N] 
87.2  
(1.12) 
[308] 
89.7 
(1.74) 
[110] 
104.5 
(2.02)  
[87] 
107.8 
(1.3)  
[101] 
p<0.001 
FEV1/FVC 
ratio 
Mean 
(SE)  
[N] 
0.64  
(0.01) 
[308] 
0.61  
(0.01)  
[110] 
0.72  
(0.01)  
[87] 
0.79  
(0.01) 
[101] 
p<0.001 
Exacerbations 
in Previous 
Year 
Mean 
(SE)  
[N] 
2.48  
(0.13) 
[310] 
2.55  
(0.26)  
[110] 
0.38  
(0.08)  
[88] 
NA p<0.001 
Pack Years Median 
(IQR)  
[N] 
2  
(1_4)  
[47] 
17.38 
(10_26) 
[110] 
4  
(1_4)  
[13] 
0.9  
(0_3)  
[20] 
<0.001 
Intubation 
(Ever) 
n/N 
(%) 
35/307 
(11) 
6/109 
(6) 
0/87 
(0) 
NA 0.083 
ICU 
Admission 
(Ever) 
n/N 
(%) 
80/307 
(26) 
18/109 
(17) 
1/86 
(1) 
NA p<0.001 
Atopy test 
positive 
n/N  
(%) 
213/272 
(78.3) 
62/87 
(71.3) 
72/78 (92.3) 36/78 
(46.2) 
p<0.001 
 264 
Table i   265 
Group Demographics 266 
FEV1: Forced Expiratory Volume in one second 267 
FVC: Forced Vital Capacity 268 
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IQR: Inter quartile range  269 
ICU: Intensive care unit  270 
NA: Not applicable 271 
SE: Standard error 272 
* 42 current smokers and 68 ex-smokers 273 
  274 
13 
 
There were more females in the SAn group (66%) compared to the other asthma groups (50%), with 275 
the age of onset of asthma 18yrs later in SAs/ex compared with SAn. Participants with severe 276 
asthma had a higher BMI than those in MMA and HC groups and were older (Table i). Both severe 277 
asthma groups experienced 2.5 exacerbations in the preceding 12 months as compared with 0.4 in 278 
the MMA group (p< 0.001).  There was a higher rate of ICU admissions in the SAn participants 279 
compared to the SAs/ex group (p<0.05). Further split of the severe asthma groups based on current 280 
and ex-smoking is presented in the online supplement (Table S5). 281 
 282 
Spirometry (Table i) 283 
FEV1 (% predicted or actual) was lower in the three asthma groups compared to the HC group 284 
(p<0.001), with the severe asthma groups having the lowest FEV1.   FVC (% predicted or actual) was 285 
also lower in both the SAn and SAs/ex groups when compared to the MMA (p<0.001) and HC groups 286 
(p<0.001). The mean FEV1/FVC ratio was lower in those with severe asthma (0.64 and 0.61, 287 
respectively) compared to the MMA (ratio 0.72, p<0.001) and HC groups (ratio 0.79, p<0.001) 288 
respectively). 289 
 290 
Medications (Table ii) 291 
Within the SAn and SAs/ex groups 46% and 45% respectively received daily OCS, and 17% and 16% 292 
respectively received anti-IgE therapy. Use of nebulised β-agonist was higher in the SAn and SAs/ex 293 
groups. Other classes of therapy were also used.  294 
  295 
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severe non-smoking 
asthma  
N=311 
 
smokers and ex-
smokers with 
severe asthma  
N=110 
 
mild/moderate 
non-smoking 
asthma  
N=88 
Oral corticosteroid n/N (%) 135/295 (45.8) 46/103 (44.7) 0/88 (0) 
Prednisolone Equ. (mg)* Mean (SE) [N] 13.2 (0.85) [122] 14.8 (1.81) [36] NA (NA) 
Inhaled corticosteroids n/N (%) 310/311 (99.7) 110/110 (100) 87/88 (98.9) 
Long acting beta agonist n/N (%) 305/309(98.7) 109/110 (99.1) 2/88 (2.3) 
Short acting beta agonist n/N (%) 260/301 (86.3) 82/105 (78.1) 68/88 (77.3) 
Injected corticosteroids n/N (%) 19/284 (6.7) 1/97 (1.0) 0/88 (0) 
Mucolytic  n/N (%) 31/286 (10.8) 18/100 (18.0) 0/88 (0) 
Anti-histamine  n/N (%) 75/311 (24.1) 16/110 (14.6) 4/88 (4.5) 
Antibiotic  (excluding 
macrolide) 
n/N (%) 11/288 (3.8) 4/98 (4.1) 0/88 (0) 
Macrolide  n/N (%) 32/311 (10.3) 13/110 (11.8) 0/88 (0) 
Long-acting muscarinic 
antagonist 
n/N (%) 65/284 (22.9) 27/97 (27.9) 0/88 (0) 
Short acting muscarinic 
antagonist 
n/N (%) 127/292 (43.5) 48/104 (46.2) 0/88 (0) 
Omalizumab  n/N (%) 50/287 (17.4) 16/98 (16.3) 0/88 (0) 
Immunosuppressant  n/N (%) 9/311 (2.9) 4/110 (3.6) 0/88 (0) 
Leukotriene modifier  n/N (%) 139/298 (46.6) 45/106 (42.5) 0/88 (0) 
Cromones n/N (%) 10/284 (3.5) 2/97 (2.1) 0/88 (0) 
Anti-fungal agent n/N (%) 5/311 (1.6) 1/110 (1.0) 0/88 (0) 
Xanthine  n/N (%) 59/289 (20.4) 21/100 (21.0) 0/88 (0) 
Nebulised beta-agonist n/N (%) 82/284 (28.9) 24/97 (24.7) 2/88 (2.3) 
 296 
Table ii 297 
Medications  298 
* Hydrocortisone and Triamcinolone doses were converted to equivalent prednisolone dose 299 
(4 healthy control participants took as required antihistamines) 300 
15 
 
Questionnaires (Table iii) 301 
ACQ and AQLQ scores reflected worse asthma control and increased morbidity in both severe 302 
asthma groups with minimal impairment in the MMA group. A similar pattern was seen with anxiety 303 
and depression. There were more upper airway symptoms measured using the SNOT20 in both 304 
severe asthma groups compared with the MMA group. Similarly the ESS scores indicated that there 305 
was an increase in sleepiness in the severe asthma groups compared to only a very mild impairment 306 
in the MMA group. 307 
  308 
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 309 
 
 
severe 
non-
smoking 
asthma  
 
N=311 
smokers 
and ex-
smokers 
with 
severe 
asthma  
N=110 
mild/moderate 
non-smoking 
asthma  
N=88 
Unadjusted 
P-value 
SA* vs. 
MMA 
Asthma control questionnaire (ACQ) 
Mean ACQ5 
Mean (SE)  
[N] 
2.28 (0.07) 
[277] 
2.23 (0.12)  
[96] 
0.86 (0.07)  
[85] 
p<0.001 
Mean ACQ7 
Mean (SE)  
[N] 
2.67 (0.08) 
[277] 
2.62 (0.12) 
[96] 
1.01 (0.07)  
[85] 
p<0.001 
Asthma quality of life questionnaire (AQLQ) 
Total 
Mean (SE)  
[N] 
4.48 (0.07) 
[276] 
4.44 (0.13)  
[92] 
5.84 (0.1)  
[84] 
p<0.001 
Symptoms 
Mean (SE)  
[N] 
4.46 (0.08) 
[276] 
4.36 (0.14)  
[92] 
5.87 (0.1)  
[84] 
p<0.001 
Emotional 
Mean (SE)  
[N] 
4.63 (0.1) 
[276] 
4.52 (0.16) 
[92] 
5.98 (0.13)  
[84] 
p<0.001 
Environmental 
stimuli 
Mean (SE)  
[N] 
4.69 (0.09) 
[276] 
4.57 (0.16)  
[92] 
5.63 (0.14)  
[84] 
p<0.001 
Activity 
limitation 
Mean (SE)  
[N] 
4.35 (0.07) 
[276] 
4.45 (0.13)  
[92] 
5.81 (0.11)  
[84] 
p<0.001 
Hospital and anxiety and depression score (HADS) 
Total 
Mean (SE)  
[N] 
12.33 (0.54) 
[223] 
13.64 (1.01) 
[72] 
7.01 (0.7)  
[70] 
p<0.001 
Anxiety 
Mean (SE)  
[N] 
6.94 (0.3)  
[223] 
7.71 (0.54)  
[72] 
4.24 (0.41)  
[70] 
p<0.001 
Depression 
Mean (SE)  
[N] 
5.39 (0.28) 
[223] 
5.93 (0.56)  
[72] 
2.77 (0.39)  
[70] 
p<0.001 
Sino-nasal outcome test 20 (SNOT 20) 
Total 
Mean (SE)  
[N] 
31.76 (1.01) 
[283] 
32.12 (1.92) 
[97] 
15.42 (1.42) [83] p<0.001 
Epworth sleepiness scale (ESS) 
Total 
Mean (SE)  
[N] 
7.48 (0.26) 
[277] 
7.95 (0.47)  
[95] 
5.49 (0.41)  
[85] 
p<0.001 
Medication adherence rating scale (MARS) 
Total 
Mean (SE)  
[N] 
22.44 (0.14) 
[278] 
22.17 (0.29) 
[94] 
21.35 (0.4)  
[84] 
0.002 
Table iii 310 
Questionnaires  311 
*SA represents SAn and SAs/ex groups combined 312 
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The MARS questionnaire scores for adherence to treatment recorded by the three asthma groups 313 
were in the range of 21 to 22, with the severe asthma groups recording higher scores (p<0.005) 314 
indicating better adherence. The AQLQ score was correlated to several variables, including FEV1 (95% 315 
CI 0.5_0.7, p<0.001), FEV1/FVC (95% CI 1.14_2.8, p<0.001), exacerbations in the previous year (95% 316 
CI -0.8_-0.2, p<0.001), BMI (95% CI -000.6_-0.002, p<0.001) and pack years smoked (95% CI -0.003_-317 
0.001, p<0.001) (Figure 3). 318 
 319 
Atopy and co-morbidities (Table iv) 320 
There was a high incidence of atopy in the 4 groups, at 70% in the asthma groups and 46% in the HC 321 
group. The incidence of allergic rhinitis, hay fever and non-allergic rhinitis were highest in the 322 
asthma groups. The HC group were much less allergic with only a third reporting hay fever and only a 323 
sixth, rhinitis or eczema.  324 
  325 
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 326 
 
 
severe 
non-
smoking 
asthma 
N=311 
smokers 
and ex-
smokers 
with 
severe 
asthma 
N=110 
Mild and 
moderate 
non-
smoking 
asthma 
N=88 
healthy 
non-
smoking 
controls 
N=101 
P-value 
P-value 
SA* vs. 
MMA 
Allergic 
rhinitis 
diagnosed 
n/N 
(%) 
164/277 
(59.2) 
44/101 
(43.6) 
42/70 
(60) 
5/30 
(16.7) 
p<0.001 0.442 
Hayfever 
diagnosed 
n/N 
(%) 
135/284 
(47.5) 
51/100 
(51) 
46/73 
(63.0) 
10/33 
(30.3) 
0.019 0.024 
Non-allergic 
rhinitis 
diagnosed 
n/N 
(%) 
42/284 
(14.8) 
17/101 
(16.8) 
8/72 
(11.1) 
1/34 
(2.9) 
0.090 0.356 
Nasal polyps 
diagnosed 
n/N 
(%) 
103/291 
(35.4) 
34/101 
(33.7) 
7/76 
(9.2) 
3/34 
(8.8) 
p<0.001 p<0.001 
Eczema 
diagnosed 
n/N 
(%) 
107/294 
(36.4) 
31/101 
(30.7) 
25/75 
(33.3) 
5/35 
(14.3) 
0.013 0.789 
GORD 
diagnosed 
n/N 
(%) 
135/289 
(46.7) 
63/99 
(63.6) 
16/75 
(21.3) 
4/35 
(11.4) 
p<0.001 p<0.001 
 327 
Table iv. Co-morbidities.  328 
GORD: Gastro-oesophageal reflux disease 329 
*SA represents SAn and SAs/ex groups combined 330 
  331 
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The presence of nasal polyps was associated with severe asthma, regardless of smoking status (4-332 
fold increased incidence in SAn and SAs/ex groups versus MMA group, p < 0.001) (Table iv). No such 333 
association was seen with allergic or non-allergic rhinitis, hay fever or reported eczema. Gastro-334 
oesophageal reflux disease was more common in severe asthma (46% SAn, 63% SAs/ex) than in 335 
MMA (21%) and HC (11%), with a greater incidence reported in the SAs/ex group versus the SAns 336 
group (p=0.004).  337 
 338 
Blood and sputum biomarkers (Table v) 339 
Blood eosinophil counts were similar in all three asthma groups. Each group had a significantly 340 
higher blood eosinophil count than the HC group (SAn vs. HC p=0.002, SAs/ex vs. HC p=0.005, MMA 341 
vs. HC p<0.001). Blood neutrophil counts were significantly higher in the severe asthma groups 342 
compared to the MMA group. 343 
  344 
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 345 
 N 
severe 
non-
smoking 
asthma 
N=311 
smokers 
and ex-
smokers 
with 
severe 
asthma 
N=110 
Mild and 
moderate 
non-
smoking 
asthma 
N=88 
healthy 
non-
smoking 
controls 
N=101 
P-value 
P-value 
SA* vs. 
MMA 
Exhaled NO 
ppb 
Median 
(IQR) [N] 
26.5 
(16_47) 
[290] 
23.5 
(12_42) 
[104] 
25 
(18_54) 
[87] 
19.25 
(13_29) 
[96] 
<0.001 0.438 
Sputum        
Sputum 
eosinophils 
(%) 
Median 
(IQR) 
[N] 
2.75 
(0_19) 
[128] 
4.13 
(1_14) 
[53] 
1.05 
(0_3) 
[43] 
0 
(0_0) 
[41] 
p<0.001 0.004 
Sputum 
neutrophils 
(%) 
Median 
(IQR) 
[N] 
53.69 
(34_75) 
[128] 
55.15 
(35_65) 
[53] 
44.5 
(26_62) 
[43] 
39.56 
(21_56) 
[41] 
0.002 0.042 
Sputum 
differential 
eosinophil 
count >1.9% 
n 
 (%) 
[N] 
74 
(57.81) 
[128]  
32 
(60.38) 
[53]  
17 
(39.53) 
[43] 
1 
(2.44)  
[41] 
<0.001 0.026 
Blood        
Blood 
eosinophils 
(%) 
Median 
(IQR) 
[N] 
2.94 
(1_6) 
[302] 
2.88 
(1_5) 
[106] 
3.00 
(2_5) 
[88] 
2.10 
(1_3) 
[101] 
0.001 0.295 
Blood  
Eosinophils 
(absolute) 
Median 
(IQR) 
[N] 
0.2 
(0.3) 
302 
0.22 
(0.29) 
106 
0.23 
(0.2) 
88 
0.1 
(0.11) 
101 
0.001 0.295 
Blood 
neutrophils 
(%) 
Median 
(IQR) 
[N] 
62 
(55_70) 
[302] 
61.75 
(55_69) 
[106] 
56.83 
(52_63) 
[88] 
57.34 
(51_64) 
[101] 
p<0.001 p<0.001 
Blood 
neutrophils 
(absolute) 
Median 
(IQR) 
[N] 
4.73 
(3.1) 
302 
4.97 
(2.87) 
106 
3.64 
(1.75) 
88 
3.03 
(1.6) 
101 
p<0.001 p<0.001 
 346 
Table v 347 
Biomarkers in blood, sputum and exhaled air  348 
*SA represents SAn and SAs/ex groups combined 349 
  350 
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Sputum samples were provided and met criteria for analysis in 44.2% of the asthma participants and 351 
40.6% of the HC group. Median sputum eosinophil counts for the SAn, SAs/ex, MMA, and HC groups 352 
were 2.75%, 4.13%, 1.05% and 0% respectively (Table v).  The sputum eosinophil count was higher in 353 
the two severe asthma groups combined compared to the mild/moderate asthma group (Table v, 354 
Fig 4).  355 
There were no significant differences in differential sputum neutrophil counts between the two 356 
severe asthma groups, which when combined were significantly higher compared to the MMA group 357 
(Table v).  358 
There was a significant negative association between log sputum eosinophils (Absolute or %) and 359 
FEV1 (% predicted or actual value) when all cohorts were considered and an adjustment for age, sex 360 
and smoking was applied. There were significant negative associations between log blood 361 
eosinophils (%) and FEV1/FVC ratio (p=0.002) and between blood neutrophils (%) and actual FEV1 362 
(p=0.002) and FEV1/FVC ratio (p=0.026). 363 
Exhaled Nitric Oxide (FeNO) (Table v) 364 
FeNO levels in all asthma groups were higher than those in the HC group, but the FeNO levels in the 365 
severe asthma groups were not different from the levels in the MMA group. The presence of nasal 366 
polyps was associated with a higher FeNO (mean increase 2.1ppb, 95% CI 1.5_2.9, p<0.001). 367 
 368 
Discussion 369 
In this large European cohort, patients with severe asthma experienced more symptoms, more 370 
exacerbations, higher levels of anxiety and depression, and a higher incidence of nasal polyps, 371 
gastro-oesophageal reflux symptoms and airflow obstruction than patients with milder disease. The 372 
clinical characteristics of asthma were present despite higher doses of treatment that included doses 373 
of inhaled corticosteroids equal or more than 1,000µg of fluticasone (or equivalent), with 45% of the 374 
combined severe asthma group receiving a daily dose of prednisolone. The characteristic features of 375 
the severe asthma U-BIOPRED cohort are similar to those reported in previous cohort studies (6, 19-376 
21). While the entry criteria for severe asthma were comparable for most of these cohort studies, 377 
the ENFUMOSA study required a lower threshold with an ICS dose of ≥ 1,200µg of budesonide or 378 
beclomethasone with at least one exacerbation in the past year. Of these 5 cohorts, the current U-379 
BIOPRED severe asthma cohort appears to be the most severe with a higher reported exacerbation 380 
rate of 2.5 per year, a reduced mean FEV1 of 67.5% of predicted and a higher proportion of patients 381 
on oral corticosteroid therapy taking a mean dose of 14 mg/day. 382 
 383 
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One of the novel features of the U-BIOPRED cohort is the inclusion of a smoking and ex-smoking 384 
severe asthma group. Patients with asthma who smoke have been reported to have poorer disease 385 
control and a reduced therapeutic response to ICS (22), possibly through the induction of 386 
corticosteroid insensitivity  (23, 24).  However our analyses of the non-smoking and the smoking/ex 387 
smoking severe asthma groups identified few differences in demographics, airway physiology, 388 
inflammatory markers and asthma symptoms between these groups. In both groups, a similar 389 
percentage received oral corticosteroid therapy; they also had similar degrees of airflow 390 
obstruction.  The slightly lower level of FeNO in the smoking/ex smoking group might be explained 391 
by an effect of current smoking (26).  One notable difference is that asthma onset occurred on 392 
average 18 years later in the smokers and ex-smokers than in the non-smokers, and yet the degree 393 
of airflow obstruction measured was similar. One interpretation is that there may be a more rapid 394 
rate of loss of lung function in the patients with asthma who smoke. The significant correlation 395 
between AQLQ scores and the number of pack-years of smoking exposure would also support a 396 
contribution of cigarette smoke to impaired quality of life in this group. We also split the 397 
demographic data of the groups by smoking status rather than severity (see Table S5) in the online 398 
supplement. This revealed that current smokers had a lower BMI compared with ex and never 399 
smokers. 400 
 401 
In agreement with the SARP study (20), patients with severe asthma (especially smokers) were less 402 
frequently atopic than those with mild/moderate disease. There was also a clear association of both 403 
nasal polyps and gastro-oesophageal reflux disease with disease severity, with approximately one-404 
third and one half reporting polyps and reflux respectively, a finding that is in keeping with previous 405 
reports (5). Nasal polyps are commonly found in severe asthma, and are associated with a 406 
particularly severe phenotype. There is evidence that treating nasal polyps with anti-IgE therapy 407 
results in better asthma outcomes (25), however whether this is due to an effect on the underlying 408 
asthma or the polyps is unknown. The link with higher FeNO levels is in keeping with work showing 409 
that nasal polypectomy leads to a fall in FeNO (26). 410 
 411 
Our findings are also similar to other studies published from severe asthma registries. In agreement 412 
with both the British Thoracic Society’s (27) and Belgium’s (28) severe asthma registries our patients 413 
are predominantly female, with a high BMI and evidence of fixed airflow obstruction. Moreover 414 
there are similarly high levels of reflux, nasal polyps and exacerbations despite greater levels of 415 
medication. 416 
 417 
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We found a greater degree of sputum eosinophilia in the two severe asthma groups compared to 418 
the mild-moderate asthma group. Up to 60% of patients in the two severe asthma groups had a 419 
differential sputum eosinophil of >1.9% (the established upper limit of normal for differential 420 
sputum eosinophil counts (29)).  This percentage is similar to previous reports in severe asthma (21). 421 
The level of sputum eosinophilia observed in the mild/moderate asthma group are also similar to 422 
those reported previously (30). 423 
 424 
The higher blood neutrophil count in participants with severe asthma may represent the effect of 425 
systemic corticosteroids which can increase blood neutrophil numbers. Sputum neutrophil counts 426 
were similar in the three asthma groups and were significantly higher than the in healthy control 427 
group. This similarly could represent the effect of corticosteroids although severe asthma has been 428 
linked to a higher level of sputum neutrophils (31, 32). 429 
 430 
The impact and burden on our participants’ health was noticeable with measures of symptoms and 431 
quality of life being far worse in severe asthma as compared to mild/moderate asthma, despite the 432 
use of higher doses and more classes of asthma treatment. Levels of anxiety and depression were 433 
also higher with severe asthma. There were significant relationships between quality of life 434 
measures and airflow obstruction, smoking history and BMI, supporting the contribution of these 435 
factors to an impairment of quality of life however the scatter of data reveals that these parameters 436 
are not closely related. The number of exacerbations experienced was greater than 2.5 437 
exacerbations per participant in both severe asthma groups in the preceding year. These findings 438 
highlight the need for an integrative assessment of clinical and physiological disease markers but 439 
additionally biological markers of disease in the assessment of severe asthma. For example, the 440 
finding that bariatric surgery has an effect on measures of airway hyper-responsiveness (33) and is 441 
associated with a lower all-cause mortality at 5 years particularly in younger, predominantly female 442 
populations (34) may point towards the need for specific and targeted intervention in people with 443 
severe asthma and obesity.  444 
 445 
There are several limitations to our study. Firstly, there is no perfect way to assess treatment 446 
adherence; however, we only approached patients managed in a specialist respiratory clinic and only 447 
those who had been assessed to be adherent were eligible for the study. Furthermore MARS scores 448 
were high indicating good levels of self-reported adherence. Secondly, subjective or historical data 449 
were assessed by questionnaire which may be prone to recall bias. Thirdly, the success rate in 450 
obtaining adequate quality sputum for analysis was in the 42-50% range and the number of 451 
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bronchoscopies was relatively lower in the SA and SAs/ex groups.  Thirdly due to the numerous 452 
formulations and inhaler devices used across Europe it was not possible to calculate the precise daily 453 
equivalent ICS dose for each participant and therefore these data are not shown, however high 454 
(>1000mcg FP) or low (<500mcg FP) dose was a study entry requirement for the severe and 455 
moderate groups respectively.  456 
 457 
We have been successful in recruiting a substantial cohort of patients with the most severe asthma 458 
that has similar characteristics to previously-reported cohorts. This gives confidence that the U-459 
BIOPRED consortium will define distinct phenotypes and endotypes of severe asthma. Matching 460 
these data to the ‘omics’ information with future unsupervised analyses will help identify new 461 
treatments for patients with severe asthma who currently have limited treatment options, and will 462 
improve our understanding of this important chronic disease. 463 
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 477 
Fig 1 478 
Visit Schedule 479 
 480 
 481 
 482 
483 
Baseline assessment 
  
Visit 2: longitudinal assessment  12 - 18 months 
after baseline visit 
Telephone call 3 – 6 months after 
Visit 2 
 
Telemonitoring 
study (optional) 
SAn and 
SAs/ex only 
Screening assessment 
All groups 
0-28 days later 
 
Visit 1 
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Figure 2 
Consort diagram 
Severe Smoking/ex-smoking Asthma 
N=110 
Subjects screened 
N= 730 
Severe non smoking asthma 
N=311 
Subjects enrolled 
N= 611 
Mild/Moderate Asthma 
N=88 
Health Controls 
N=101 
Questionnaires n= 277 
Spirometry n= 308 
Medical history n= 311 
Blood n=302 
Sputum n=128 
Urine n=311 
CT scan n= 280 
GWAS n=311 
Bronchoscopy=64 
Questionnaires n= 96 
Spirometry n=110 
Medical history n=110 
Blood n=106 
Sputum n= 53 
Urine n=110 
CT scan n= 96 
GWAS n=55 
Bronchoscopy n=9 
Questionnaires n= 85 
Spirometry n= 87? 
Medical history n=89 
Blood n=88 
Sputum n= 43 
Urine n=88 
CT scan n=88 
GWAS n=88  
Bronchoscopy n=40 
Questionnaires N/A 
Spirometry n=101 
Medical history N/A 
Blood n= 101 
Sputum n=41 
Urine n =101 
CT scan n= 91 
GWAS n=96 
Bronchoscopy n=46  
Screen Failure n=94 
Adverse events n=4 
Lost to follow up n=2 
Withdrew consent n= 7 
Participated in another study n=1 
Other reasons n=11 
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Figure 3  
Contour plots of AQLQ related to baseline demographics 
 
Figures represent scatter plots describing the relationship between each factor and the asthma 
quality of life z-score. The contour lines are coloured blue to red, to indicate increasing density of 
points in the graph.  The density was modelled using two-dimensional kernel density estimation. The 
contour plots show weak inverse relationships and particularly the scatter between quality of life 
and exacerbations, BMI and pack years, a strong inverse relationship between quality of life and 
asthma control and weak positive relationships between quality of life and measures of lung 
function. 
 
28 
 
Fig 4A 
Eosinophil counts by group 
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Fig 4B 
Neutrophil counts by group 
 
Fig 4 
A) sputum eosinophil count and B) sputum neutrophil count, by cohort.  The box and whisker plots 
are shaded in pale blue, with outliers denoted by open circles.  The raw data are given by dark blue 
points overlaid.    
SAn; Severe non-smoking asthma 
SAs/ex; Smokers and ex-smokers with severe asthma 
MMA; Mild/moderate non-smoking asthma 
HC; Healthy non-smoking controls  
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